Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0000000000001942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrence of clozapine associated bicytopenia (Leucopenia and Anaemia) while rechallenge: A case report.
Asian J Psychiatr
July 2023
Post Graduate Institute of Medical Education & Research, Chandigarh, India. Electronic address:
Successful rechallenge after clozapine-associated myocarditis.
BMJ Case Rep
May 2022
Psychiatry, NHS Ayrshire and Arran Woodland View, Irvine, UK.
Clozapine is a highly effective medication used in management of treatment-resistant schizophrenia. Clozapine-associated myocarditis (CAM) is a rare but increasingly recognised complication of clozapine titration. Following an episode of CAM, clinicians can face a challenging dilemma of balancing the risks of recurrent myocarditis against the harms of ongoing psychosis.
View Article and Find Full Text PDFSuccessful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report.
BMC Pharmacol Toxicol
May 2020
National Psychosis Unit, Bethlem Royal Hospital, London, UK.
Background: Acute pancreatitis is a rare but recognised complication of clozapine leading to termination of treatment.
Case Presentation: We present the case of a 39-year-old man with treatment-resistant schizoaffective disorder and a history of recurrent acute pancreatitis attributed to clozapine. After 15 years of unremitting symptoms with disruptive and aggressive behaviour, he was admitted for a clozapine rechallenge.
Clozapine Rechallenge Following Neuroleptic Malignant Syndrome: A Systematic Review.
J Clin Psychopharmacol
February 2020
Department of Psychiatry, School of Medicine and Medical Sciences, University College.
Purpose/background: Neuroleptic malignant syndrome (NMS) has been described with most antipsychotics, most commonly first generation. Clozapine has also been associated with NMS.
Methods/procedures: We conducted a systematic review to identify all studies investigating or describing (a) clozapine rechallenge following suspected NMS associated with clozapine, (b) clozapine use after suspected NMS associated with another antipsychotic, and (c) rechallenge with nonclozapine antipsychotics after suspected clozapine-associated NMS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!